Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 11 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

27%

3 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

10Total
Not Applicable (7)
P 3 (1)
P 4 (2)

Trial Status

Recruiting5
Not Yet Recruiting2
Unknown2
Enrolling By Invitation1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 1 completed trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT06843005Not ApplicableRecruiting

Serial Coronary CTA-based Plaque Progression Detection for Management of Coronary Heart Disease

NCT07439133Phase 3RecruitingPrimary

Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR)

NCT07386418Not ApplicableRecruiting

Study of Lesion-Specific Invasive Haemodynamic Angina Thresholds

NCT07306728Not ApplicableNot Yet RecruitingPrimary

Effect of Femoral Region Ice Bag Application on Patients' Clinical Outcomes Post-Percutaneous Coronary Intervention

NCT07163858Not ApplicableRecruiting

Postural Mobilization Compared to Noradrenaline Only in Off-Pump CABG Surgery

NCT07162792Not ApplicableNot Yet RecruitingPrimary

The Safety and Efficacy of New-Generation BRS vs. DCB for De Novo Large Coronary Artery Lesions: A Prospective RCT

NCT07158307Enrolling By InvitationPrimary

Safety and Efficacy of GENOSS® DCB With a Shellac Plus Vitamin E Excipient in Patients With De Novo Lesion

NCT07107568Not ApplicableRecruiting

Assessment of Coronary Artery Disease Before Transcatheter Aortic Valve Replacement: A Randomized, Multicenter, Non-Inferiority Trial

NCT03072121Phase 4UnknownPrimary

Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization

NCT03072082Phase 4UnknownPrimary

Curative Effect Evaluation of Danlou Tablet on Coronary Artery Disease Not Amenable to Revascularization

NCT01839071Not ApplicableCompletedPrimary

Influence of Vasculary Inflammation on Development of Diabetes

Showing all 11 trials

Research Network

Activity Timeline